Overall, we here provide novel data regarding expression—especially of PGRMC1 and σ2/TMEM97, for which very little is known [9]—in different human cancer types and cell lines included in a significant tool for anticancer drug development, the NCI60 cell line panel. This evidence concerns the gene PGRMC1 and cancer.